Emulate
PrivateLast Round
Series E
Sep 7, 2021
Total Funding Raised
$175M
Company Overview
Emulate is a biotechnology company that offers an automated bio-emulation platform to accurately predict human responses to diseases, medicines, chemicals, and foods by integrating micro-engineering with living human cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Emulate Comparables
Compare Emulate with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CN Bio | 92% | |
| AIM Biotech | 87% | |
| AlveoliX AG | 86% |
Emulate Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Sep 7, 2021 | ||||
| Series C | Jun 19, 2018 | ||||
| Series B Extension | Oct 20, 2016 | ||||
| Series B | Mar 28, 2016 | ||||
| Series A | Jul 28, 2014 |
Key People
Founding team and executive leadership
Emulate Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SciFi Ventures | Series C |
| Perceptive Advisors | Series E |
| Founders Fund | Series C |
| +ND Capital | Series B, Series B Extension, Series A |
| ALS Investment Fund | Series C |
| OS Fund | Series B, Series B Extension |
| ATEL Capital Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 13, 2026
Liver-Chip BioKit validated under FDA's ISTAND program.
- Feb 27, 2026
Attended SLAS 2026 and won a New Product Award.
Recent news
Latest coverage and updates
- has_valuationSep 18, 2026
Emulate, Inc. had valuation of $3.7B on Sep 1st '26.
Emulate Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Emulate's valuation, stock price, and market status.
Is Emulate a public or private company?
Emulate is a private company.
What is the current stock price of Emulate?
Emulate is a private company with no public stock price. No recent secondary market data is available.
How much is Emulate worth (valuation)?
Valuation information for Emulate is not publicly available.
Can I buy Emulate stock?
Emulate shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Emulate's last funding round?
Emulate's most recent funding round was Seed Round on June 18, 2026.
Who are the main investors in Emulate?
Key investors in Emulate include Perceptive Advisors, Founders Fund, +ND Capital, OS Fund, ATEL Capital Group.
Will Emulate IPO soon?
No public IPO plans have been announced for Emulate.
How can I track Emulate secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Emulate's secondary market activity and sign up for updates.